<DOC>
	<DOCNO>NCT00728793</DOCNO>
	<brief_summary>This phase I , open-label , dose-escalation study CUDC-101 patient advance refractory solid tumor . CUDC-101 multi-targeted agent design inhibit epidermal growth factor receptor ( EGFR ) , human epidermal growth factor receptor Type 2 ( Her2 ) histone deacetylase ( HDAC ) . The study design establish safety , include maximum tolerated dose , pharmacokinetics , anti-tumor activity CUDC-101 .</brief_summary>
	<brief_title>A Phase I Study Safety , Pharmacokinetics , Anti-Tumor Activity CUDC-101 Patients With Advanced Solid Tumors</brief_title>
	<detailed_description />
	<criteria>Subjects advance , refractory solid tumor histopathologically confirm diagnosis Subjects must standard care option refuse standard therapy Measurable evaluable disease Age ≥ 18 year ECOG performance &lt; 2 Life expectancy ≥ 3 month If female , neither pregnant lactating If child bear potential , must use adequate birth control Absolute neutrophil count ≥ 1,500/µL ; platelet ≥ 100,000/µL ; Creatinine ≤ 1.5x upper limit normal ( ULN ) calculate creatinine clearance ≥ 60mL/min/1.73m2 Total bilirubin ≤ 1.5x ULN ; AST/ALT ≤ 2.5x ULN . In subject document liver metastasis , AST/ALT may ≤ 5x ULN Prothrombin time ≤1.5x ULN , unless receive therapeutic anticoagulation Serum magnesium potassium within normal limit ( may supplement achieve normal value ) Subjects brain metastasis eligible control stable dose ≤ 10mg prednisone/day equivalent dose steroid Able render inform consent follow protocol requirement . Anticancer therapy within 4 week study entry . Prostate cancer subject LHRH hormonal therapy may enrol continue therapy . Use investigational agent ( ) within 30 day study entry History cardiac disease New York Heart Association ( NYHA ) Class II great congestive heart failure ( CHF ) , myocardial infarction ( MI ) unstable angina past 6 month prior Day 1 treatment , serious arrhythmia require medication treatment . Known infection human immunodeficiency virus ( HIV ) , hepatitis B hepatitis C. The following permit used caution suitable agent use possible : Subjects receive concomitant medication metabolize CYP 3A4 CYP 2D6 CYP3A4 inducer CYP3A4 inhibitor Warfarin</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2011</verification_date>
	<keyword>Advanced Solid Tumors</keyword>
	<keyword>EGFR</keyword>
	<keyword>HDAC</keyword>
	<keyword>Her2</keyword>
	<keyword>Open-Label</keyword>
	<keyword>Dose-Escalation</keyword>
</DOC>